Nalaganje...

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review

INTRODUCTION: Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate represented a major therapeutic advance over conventional CML therapy, with more than 90% of patients obtaining complete hematologic respo...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Jabbour, Elias, Cortes, Jorge, Kantarjian, Hagop
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2010
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2899790/
https://ncbi.nlm.nih.gov/pubmed/20694077
Oznake: Označite
Brez oznak, prvi označite!